Exicure gets Nasdaq extension as Exicure stock faces USD 2.50 million test

Published on 10/15/2026 at 13:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exicure stock costs EUR 1.06 on October 15, 2026. The Nasdaq deadline is December 2, 2026, with USD 2.50 million of equity required.

Nasdaq compliance deadline approaches

Exicure received a Nasdaq extension to December 2, 2026, for a USD 2.50 million equity requirement.
Exicure issued USD 1.00 million in shares for a clinical milestone payment on August 3, 2026.
Exicure stock trades at EUR 1.06 at 1:01 p.m. CEST at Lang & Schwarz on October 15, 2026.
Exicure has a USD 7.9 million market capitalization and a USD 0.94 to USD 9.48 52-week range.

XCUR, US30205M3097, Illustration mit AI erstellt.

Exicure (ISIN US30205M3097) was trading at EUR 1.06 at Lang & Schwarz on October 15, 2026, at 1:01 p.m. CEST. The company had until December 2, 2026, to restore Nasdaq compliance by meeting a USD 2.50 million minimum stockholders' equity requirement, as Ground News reported on September 20, 2026.

Nasdaq deadline sets the frame

The extension gives Exicure a defined compliance date while its market value remains modest. Investing.com listed a USD 7.92 million market capitalization and a USD 0.94 to USD 9.48 52-week range on October 15, 2026.

Exicure's business profile centers on nucleic acid therapies and a co-development agreement involving Burixafor, also known as GPC-100. Stock Analysis identifies the company as a healthcare biotechnology issuer listed on Nasdaq.

What does the deadline mean?

The USD 2.50 million threshold is the immediate financial test. For investors, the key distinction is between the deadline and the amount: Exicure has until December 2, 2026, to address the equity requirement rather than simply maintain a listing notice.

Three steps shaped the year

On June 30, 2026, Exicure announced board changes that added two directors and expanded the board to six, according to Investing.com. On August 3, 2026, the company planned to issue shares worth USD 1.00 million to settle a clinical milestone payment. On September 16, 2026, Exicure received the Nasdaq extension carrying the December 2 deadline.

Next date is December 2

The next substantiated date is December 2, 2026, the Nasdaq compliance deadline. The date gives the market a concrete point for judging whether the equity requirement has been addressed.

Stock stays tied to compliance

Exicure operates in biotechnology and remains closely linked to the outcome of its Nasdaq equity test. Its small USD 7.92 million market capitalization puts the USD 2.50 million requirement at the center of the near-term investment case.

Exicure was trading at EUR 1.06 at Lang & Schwarz on October 15, 2026, at 1:01 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Exicure stock.